Effective HIV care benefited all HIV patients, regardless of demographics and behavioral risk

Key points
- Improved treatment options, a multi-pronged treatment model, and federal funding from the Ryan White Program have helped an inner city Baltimore clinic improve outcomes for HIV patients across all groups, including those most often hardest hit by the disease.
- Current antiretroviral therapy is so effective that when such care is delivered by expert clinicians in a supportive environment, the prognosis for patients is measurably enhanced.
- The Baltimore clinic's care model has multiple levels to address HIV patients' complex needs: primary, specialty (substance abuse and mental health), and supportive care (case-management, nutrition, treatment adherence, emergency services, and transportation).
- Health care stumbling blocks for patients with HIV include inadequate access to treatment, lack of retention in care, and poor adherence to current HIV treatment guidelines.
Improved treatment options, a multi-pronged treatment model, and federal funding from the Ryan White Program have helped an inner city Baltimore clinic improve outcomes for HIV patients across all groups, including those most often hardest hit by the disease. Published in Clinical Infectious Diseases, the results from the 15-year analysis of patients at a clinic serving a primarily poor, African-American patient population with high rates of injection drug use demonstrate what state-of-the-art HIV care can achieve, given appropriate support.
Current antiretroviral therapy is so effective that when such care is delivered by expert clinicians in a supportive environment, the prognosis for patients is measurably enhanced. "Contemporary HIV care can markedly improve the health of persons living with HIV regardless of their gender, race, risk group, or socioeconomic status," said study author Richard D. Moore, MD, MHS, of Johns Hopkins University in Baltimore. The study by Dr. Moore and colleagues Jeanne C. Keruly, MS, and John G. Bartlett, MD, which analyzed data collected from 1995 to 2010, is the first to directly compare outcomes for patient groups defined by these variables, often the groups affected most by health-care disparities.
The Baltimore clinic's care model has multiple levels to address HIV patients' complex needs: primary, specialty (substance abuse and mental health), and supportive care (case-management, nutrition, treatment adherence, emergency services, and transportation). Supported in part by the federally funded Ryan White Program, created in 1990, the clinic receives financial assistance to provide HIV care to low-income patients, who in the 2010 fiscal year made up 92 percent of the clinic's patients.
Health care stumbling blocks for patients with HIV include inadequate access to treatment, lack of retention in care, and poor adherence to current HIV treatment guidelines. The Ryan White Program allowed this urban clinic to provide care to patients who might otherwise have slipped through the cracks, the study authors noted. As a result of the "integrated multi-disciplinary program of care" the clinic was able to offer, and because of advances in antiretroviral drugs, HIV-infected patients at the clinic now have a life expectancy of 73 years. This longevity remained the same across all demographic and behavioral risk groups. Even adjustments made for patients' source of medical insurance did not affect the outcomes.
There is one important caveat: The study's results include only those patients who were sufficiently "engaged in care" to show up for lab testing and clinical follow-ups. "Getting people living with HIV engaged in care is critical to their well-being," Dr. Moore said. "As investigators as well as our patients' clinicians, we were gratified to find that, with the support of the Ryan White HIV/AIDS Program, we have created a medical home that is able to deliver highly beneficial HIV medications and other therapy to all of our patients."
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
NewsDrug that reduces abdominal fat in HIV patients also may reduce fat in liver
The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such…
21 July 2014
NewsGrowth hormone analog may reduce risk of fatty liver disease in HIV-infected patients
In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study…
21 July 2014
NewsHepatitis C cured in co-infected HIV patients
A multicenter team of researchers report that in a phase III clinical trial, a combination drug therapy cures chronic hepatitis C in the majority of patients co-infected with both HIV and hepatitis C. "In many settings,…